KRAS and non-small cell lung carcinoma: To this purpose, we treated NSCLC A549 cells with different αEGFR-antibody-protamine-complexes with control (scrambled, scr) vs. anti-KRAS siRNA, respectively, and cultured equal numbers of cells in soft agar for anchorage-independent colony growth indicative for tumourigenicity.